Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment with Subcutaneous Immunoglobulin
Sponsor: CSL Behring
Enrolling: Male and Female Patients
IRB Number: AAAJ7602
U.S. Govt. ID: NCT01545076
Contact: Jacqueline Scoon: 212-305-3839 / js4462@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see how effective two doses of an investigational new drug called IgPro20 is when given subcutaneously (a shot given into the fat layer between the skin and the muscle) to treat CIDP in patients that still require IVIG and also to look at how safe the IgPro20 is for patients.
This study is closed
Thomas Brannagan, MD
Do You Qualify?
Do you have a history of thrombotic episodes within the past 2 years? Yes No
Do you have any severe disease or condition that would most likely interfere with your participation in this study? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Jacqueline Scoon